Telo Genomics Corp Stock Operating Margin
TDSGF Stock | USD 0.07 0.01 13.58% |
Telo Genomics Corp fundamentals help investors to digest information that contributes to Telo Genomics' financial success or failures. It also enables traders to predict the movement of Telo OTC Stock. The fundamental analysis module provides a way to measure Telo Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Telo Genomics otc stock.
Telo |
Telo Genomics Corp OTC Stock Operating Margin Analysis
Telo Genomics' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Competition |
Based on the recorded statements, Telo Genomics Corp has an Operating Margin of 0.0%. This is 100.0% lower than that of the Health Care Technology sector and 100.0% lower than that of the Health Care industry. The operating margin for all United States stocks is 100.0% lower than that of the firm.
Telo Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Telo Genomics' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Telo Genomics could also be used in its relative valuation, which is a method of valuing Telo Genomics by comparing valuation metrics of similar companies.Telo Genomics is currently under evaluation in operating margin category among its peers.
Telo Fundamentals
Return On Equity | -0.78 | |||
Return On Asset | -0.45 | |||
Current Valuation | 13.73 M | |||
Shares Outstanding | 59.42 M | |||
Shares Owned By Insiders | 6.52 % | |||
Shares Owned By Institutions | 1.83 % | |||
Price To Earning | (0.67) X | |||
Price To Book | 10.46 X | |||
EBITDA | (2.05 M) | |||
Net Income | (2.11 M) | |||
Cash And Equivalents | 2.69 M | |||
Cash Per Share | 0.05 X | |||
Total Debt | 40 K | |||
Debt To Equity | 0.01 % | |||
Current Ratio | 14.66 X | |||
Book Value Per Share | 0.04 X | |||
Cash Flow From Operations | (1.79 M) | |||
Earnings Per Share | (0.03) X | |||
Number Of Employees | 16 | |||
Beta | 1.87 | |||
Market Capitalization | 12.81 M | |||
Total Asset | 2.83 M | |||
Net Asset | 2.83 M |
About Telo Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Telo Genomics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Telo Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Telo Genomics Corp based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Telo OTC Stock
Telo Genomics financial ratios help investors to determine whether Telo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Telo with respect to the benefits of owning Telo Genomics security.